MedTrace Logo

The remedē® System for the Treatment of Central Sleep Apnea in Daily Practice

NCT02577445 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2017-04-06

Study results available
· View outcomes & findings →

Summary

The aim of this post market study is to assess the impact of sleep-disordered breathing on the well-being of patients according to the treatment chosen, i.e. with or without implantation of the remedē® system to treat sleep-disordered breathing.

Conditions

Sponsors & Collaborators

  • Respicardia, Inc.

    collaborator INDUSTRY

  • LivaNova

    lead INDUSTRY

Principal Investigators

  • Christoph Stellbrink · Bielefeld-Klinikum

  • Stefan Anker · Herzzentrum Göttingen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02577445 on ClinicalTrials.gov